Navigation Links
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Date:12/2/2009

nt pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete cl
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
2. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
3. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
7. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
8. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Celtaxsys, Inc., a ... including those with rare and orphan inflammatory disease indications, ... U.S. Food and Drug Administration (FDA) to begin a ... acebilustat (CTX-4430), in adult CF patients in the US. ... Europe will be filed soon after. ...
(Date:7/6/2015)... SAN FRANCISCO, Calif. , July 6, 2015 /PRNewswire/ ... global pharmaceutical company, and Oculeve, a development-stage medical device ... disease, today announced that they have entered into an ... all-cash transaction.  Under the terms of the agreement, Allergan ... and commercialization milestone payments related to Oculeve,s lead development ...
(Date:7/6/2015)... China Information Technology, Inc. (the "Company" or "CNIT") (Nasdaq ... exchange, and big data solutions in China ... mobile app for Healthcare One Pass, ushering in a ... The Company jointly hosted the launch ceremony with the ... News Net.   The mobile app for Healthcare ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... hospitals scramble to adopt the patient-centered focus that is ... at improving healthcare in the U.S., LodgeNet Healthcare ... engagement solution that encourages patients to become educated, active ... to interact with patients throughout the entire continuum of ...
... EAST BRUNSWICK, N.J. and EDISON, N.J., June 8, ... today announced they had entered into a broad-based ... controlled release products. Under the terms of the ... develop and manufacture products for Amerigen to commercialize ...
Cached Medicine Technology:LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 2LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 3LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 4Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products 2
(Date:7/6/2015)... ... ... Olive Fertility Centre is proud to announce that Olive medical director Dr. Jason ... department of Family Practice. , “This award is a real honour,” says Dr Hitkari. ... changing so rapidly and we are also developing new models of patient-centred care that ...
(Date:7/6/2015)... CA (PRWEB) , ... July 06, 2015 , ... Seedstock ... deliver the keynote address at the 4th Annual Seedstock Sustainable Agriculture Conference – “Innovation ... year’s conference , held at the University of California-San Diego, will explore solutions ...
(Date:7/6/2015)... Livonia, MI (PRWEB) , ... July 06, 2015 , ... ... Group has teamed up with Livonia Save Our Youth and announced a new charity ... young people in regards to alcohol and drug abuse. Livonia Save Our Youth is ...
(Date:7/6/2015)... ... July 06, 2015 , ... Orthopaedic & Spine ... 100th case using SpineFrontier’s® PedFuse® REmind® Screws. The operation took place on Tuesday, ... The procedure was an L5-S1 posterior lumbar interbody fusion on a 69 year ...
(Date:7/5/2015)... Boston, MA (PRWEB) , ... July 06, 2015 , ... ... Boston Triathlon. City Sports will co-produce two training clinics for first-time triathletes this summer ... two clinics will take place on Thursday, July 9, at 6:00 p.m. at the ...
Breaking Medicine News(10 mins):Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 3Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 4Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 2Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 3Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 2Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 3
... , , , REDMOND, ... meeting that seeks solely to personally enlighten and transform the people ... annual meeting under the vision of Chairman and CEO Dwayne ... memory care communities, Aegis Living is in the business of taking ...
... , WASHINGTON , Jan. ... announced that it has filed a motion for immediate relief ... Georgia from the imminent and serious threat of ... late yesterday, seeks appointment of a monitor who will set ...
... online resources, coping tips , FRIDAY, Jan. 29 (HealthDay ... for 75 percent of adult cancer patients, according to ... , Breakthrough cancer pain refers to sudden, temporary flares ... is taking pain medication. , "We,re not talking about ...
... when caught early. But in a third of cases, ... when cure is much less likely. , Quicker identification ... mathematical model developed by researchers at the Ohio State ... Richard J. Solove Research Institute., The model uses information ...
... Association of Physicists in Medicine (AAPM) has issued a statement ... New York Times yesterday and earlier in the week that ... last decade involving people undergoing radiation therapy. While it ... the statement acknowledges their gravity. It reads in part: "The ...
... 2010 Investigators from the International Center for Biomedicine ... Center for Bioinformatics of the Universidad de Talca, have ... astemizole, may be suitable for use as PET (positron ... detection of Alzheimer,s Disease. The study is published in ...
Cached Medicine News:Health News:Aegis Living's CEO Transforms Business As Usual One Employee At a Time 2Health News:Aegis Living's CEO Transforms Business As Usual One Employee At a Time 3Health News:Justice Department Files for Immediate Relief Regarding Conditions in Georgia's Hospitals 2Health News:Justice Department Files for Immediate Relief Regarding Conditions in Georgia's Hospitals 3Health News:Justice Department Files for Immediate Relief Regarding Conditions in Georgia's Hospitals 4Health News:Three-Fourths of Cancer Patients Have Severe Flares of Pain 2Health News:Three-Fourths of Cancer Patients Have Severe Flares of Pain 3Health News:Curing more cervical cancer cases may be in the math 2Health News:AAPM statement on quality radiation therapy 2Health News:Promising new neuroimaging techniques for early detection of Alzheimer's disease 2
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... Marlin' Cervical Orthosis ensures ... semirigid molded polyethylene anterior frame ... allows free air flow and ... facilitates height adjustment. For added ...
... Aspen® Cervical Collars improves patient compliance, ... costs. Adjusts to user's anatomy, wicks ... head weight to shoulders and upper ... Front and back airflow openings. Adjustable ...
... Designed with patient need and comfort ... Appliance) family of products effectively address ... The Chairback frame attachment provides optimal ... (LSO) provides superior support for patient ...
Medicine Products: